Clinical trials: Vincristine
Neuroblastoma
Combination Chemotherapy and Surgery With or Without Radiation Therapy in Treating Patients With Stage 2 or Stage 3 Neuroblastoma
RATIONALE: Drugs used in chemotherapy, such as vincristine, cyclophosphamide, cisplatin, etoposide, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from…
- Trial name
- NCT00416676
- Testing
- carboplatin, cisplatin, cyclophosphamide
- Volunteers
- 30 people
- Sponsor
- Children's Cancer and Leukaemia Group
Extragonadal Germ Cell Tumor, Teratoma
Combination Chemotherapy in Treating Male Patients With Germ Cell Tumors
RATIONALE: Drugs used in chemotherapy, such as cisplatin, vincristine, bleomycin, carboplatin, and etoposide phosphate, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them…
- Conditions
- Extragonadal Germ Cell Tumor, Teratoma, Testicular Germ Cell Tumor
- Trial name
- NCT00301782
- Testing
- bleomycin sulfate, carboplatin, cisplatin
- Where
- 20 sites in United Kingdom
- Volunteers
- 88 people
- Sponsor
- Medical Research Council
Medulloblastoma
Reduced Craniospinal Radiation Therapy and Chemotherapy in Treating Younger Patients With Newly Diagnosed WNT-Driven Medulloblastoma
This phase II trial studies how well reduced doses of radiation therapy to the brain and spine (craniospinal) and chemotherapy work in treating patients with newly diagnosed type of brain tumor called WNT)/Wingless (WNT)-driven…
- Trial name
- NCT02724579
- Testing
- Cisplatin, Cyclophosphamide, Laboratory Biomarker Analysis
- Where
- 195 sites in United States, Australia and 3 more
- Volunteers
- 45 people
- Sponsor
- Children's Oncology Group
Diffuse Large B-Cell Lymphoma, Non-Hodgkin's Lymphoma
A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1, 2 or 3a
This multi-center, open-label, randomized study will evaluate the participant preference with subcutaneous versus intravenous administration of MabThera/Rituxan (rituximab) in participants with CD20+ diffuse large B-cell lymphoma…
- Trial name
- NCT01724021
- Testing
- Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisone/Prednisolone (CHOP), Cyclophosphamide, Vincristine, Prednisone/Prednisolone (CVP), Bendamustine
- Where
- 246 sites in Argentina, Australia and 30 more
- Volunteers
- 743 people
- Sponsor
- Hoffmann-La Roche
Leukemia
Combination Chemotherapy in Treating Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT01005758
- Testing
- cyclophosphamide, cytarabine, dexamethasone
- Volunteers
- 180 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Leukemia
Combination Chemotherapy and Radiation Therapy in Treating Patients With Acute Lymphoblastic Leukemia That Has Relapsed in the CNS or Testes
RATIONALE: Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer cells.
- Trial name
- NCT00096135
- Testing
- filgrastim, cyclophosphamide, cytarabine
- Where
- 153 sites in United States, Australia and 3 more
- Volunteers
- 168 people
- Sponsor
- Children's Oncology Group
Lymphoma
Genes in Predicting Outcome of Patients With DLBCL Treated With Rituximab and Combination Chemotherapy (R-CHOP)
The investigators hypothesize that survival of newly diagnosed DLBCL (diffuse large B-cell lymphoma) patients treated with R-CHOP can be predicted by RNA or protein gene expression or by presence of biomarkers associated with the…
- Trial name
- R-CHOP (NCT00450385)
- Testing
- Rituximab, Cyclophosphamide, Doxorubicin
- Where
- 5 sites in United States
- Volunteers
- 57 people
- Sponsor
- University of Miami
Leukemia, Lymphoma
Bryostatin 1 in Treating Patients With Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00002908
- Testing
- bryostatin 1, vincristine sulfate
- Where
- United States
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Mantle Cell Lymphoma
R-CHOP + R-HAD vs R-CHOP Followed by Maintenance Lenalidomide + Rituximab vs Rituximab for Older Patients With MCL
This study aims to evaluate whether the addition of lenalidomide to rituximab-maintenance improves progression free survival (PFS) compared to standard rituximab maintenance after induction treatment consisting of R-CHOP + R-HAD…
- Trial name
- NCT01865110
- Testing
- R-CHOP, R-CHOP / R-HAD, Rituximab
- Where
- 143 sites in Belgium, France and 5 more
- Volunteers
- 623 people
- Sponsor
- The Lymphoma Academic Research Organisation
Lymphoma
Combination Chemotherapy Plus Rituximab in Treating Patients With Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma
RATIONALE: Monoclonal antibodies such as rituximab can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells.
- Trial name
- NCT00005959
- Testing
- filgrastim, rituximab, cyclophosphamide
- Where
- 27 sites in United States
- Sponsor
- Amgen
Lymphoma
Comparison Study of Doxorubicin Versus Epirubicin-induced Cardiotoxicity in Patients With DLBCL
The aim of this study is to compare CHOP versus CEOP-induced cardiotoxicity in patients with aggressive B-cell lymphoma. The hypothesis is epirubicin is associated with less cardiotoxicity without compromising the efficacy.
- Trial name
- NCT00854568
- Testing
- CEOP regimen, CHOP regimen
- Where
- China
- Volunteers
- 398 people
- Sponsor
- Fudan University
Lymphoma, B-Cell
Study Evaluating Chemotherapy in Combination With Inotuzumab Ozogamicin In Subjects With Non-Hodgkin's Lymphoma
This is a phase 1 trial designed to evaluate safety and tolerability of chemotherapy in combination with inotuzumab ozogamicin, an investigational product, in adults with CD22-positive non-Hodgkin's lymphoma.
- Trial name
- NCT01055496
- Testing
- inotuzumab ozogamicin+rituximab +cyclophosphamide+vincristine+prednisone, inotuzumab ozogamicin+rituximab+gemcitabine+cisplatinum+dexamethasone
- Where
- 28 sites in United States, Belgium and 7 more
- Volunteers
- 103 people
- Sponsor
- Pfizer
Low-grade Glioma, Pediatric Brain Tumor
Study of Recombinant Human Endostatin Combined With CV Regimen in the Treatment of Pediatric Low-grade Gliomas
Low-grade gliomas (LGGs) are the most common intracranial tumors in children, accounting for about 40% of intracranial tumors in children.
- Trial name
- NCT04659421
- Testing
- combined therapy with rh-ES and CV
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Beijing Sanbo Brain Hospital
Lymphoma
Lenalidomide, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large Cell or Follicular B-Cell Lymphoma
RATIONALE: Lenalidomide may stimulate the immune system in different ways and stop cancer cells from growing. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways.
- Trial name
- NCT00670358
- Testing
- pegfilgrastim, rituximab, cyclophosphamide
- Where
- 3 sites in United States
- Volunteers
- 138 people
- Sponsor
- Mayo Clinic
Hodgkin Lymphoma
Brentuximab for Newly Diagnosed Hodgkin Disease
The addition of Brentuximab vedotin (Bv) to combination chemotherapy will be safe, well tolerated and effective in children, adolescents and young adults with all stages of newly diagnosed Hodgkin lymphoma (HL).
- Trial name
- NCT02398240
- Testing
- Brentuximab Vedotin, Doxorubicin, Vincristine
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Mitchell Cairo
Lymphoma
SAHA + CHOP in Untreated T-cell Non-Hodgkin's Lymphoma
The goal of this clinical research study is to find out how well the drug Zolinza (vorinostat) works in combination with the drug combination called CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) to treat…
- Trial name
- NCT00787527
- Testing
- Zolinza (vorinostat), Cyclophosphamide, Doxorubicin
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- M.D. Anderson Cancer Center
Diffuse Large B-Cell Lymphoma
MabionCD20 Compared to MabThera in Lymphoma Patients
The aim of the study is to demonstrate the high level of biosimilarity between MabionCD20 (MABION SA) and the reference product: MabThera (rituximab by Hoffman-La Roche) in patients with CD20-positive diffuse large B-cell…
- Trial name
- MADILYM (NCT02617485)
- Testing
- Rituximab, Doxorubicin, Vincristine
- Where
- 35 sites in Bosnia and Herzegovina, Croatia and 5 more
- Volunteers
- 143 people
- Sponsor
- Mabion SA
B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, T Acute Lymphoblastic Leukemia
Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia
This phase II trial tests how well etoposide, prednisone, vincristine, cyclophosphamide and doxorubicin (DA-EPOCH) with or without rituximab plus recombinant Erwinia asparaginase (JZP458) works in treating patients with newly…
- Trial name
- NCT06738368
- Testing
- Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Bone Marrow Collection
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Washington
Multiple Myeloma
Effects of Exercise in Combination With Epoetin Alfa
The purpose of the study was to determine the effect of Epoetin alfa therapy (short term versus long term) with and without a home-based individualized exercise program that incorporated aerobic and strength resistance training…
- Trial name
- NCT00577096
- Testing
- Epoetin Alfa, Exercise, Autologous Peripheral Blood Stem Cell Transplantation
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- University of Arkansas
Diffuse Large B-Cell Lymphoma (DLBCL)
Birelentinib Plus R-CHOP in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma (TAI-SHAN19)
This study will treat patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL). It will assess the anti-tumor efficacy and safety of birelentinib plus rituximab, cyclophosphamide, doxorubicin, vincristine, and…
- Trial name
- NCT07712588
- Testing
- Birelentinib, Rituximab, Cyclophosphamid
- Where
- 5 sites in China
- Volunteers
- 880 people
- Sponsor
- Dizal Pharmaceuticals